345 Participants Needed

RO7673396 for Cancer

Recruiting at 4 trial locations
RS
Overseen ByReference Study ID Number: YO45758 https://forpatients.roche.com/
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This study aims to evaluate the safety and tolerability of RO7673396 in participants with advanced solid tumors harboring RAS mutation(s). This study consists of two stages: Stage 1 (Dose Escalation) and Stage 2 (Dose Expansion). Stage 1 will define the recommended dose(s) for expansion (RDEs) of RO7673396. Stage 2 will evaluate preliminary anti-tumor activity of the RDE(s) defined in Stage 1 and of other doses of interest for future development in selected solid tumor indications.

Who Is on the Research Team?

CT

Clinical Trials

Principal Investigator

Hoffmann-La Roche

Are You a Good Fit for This Trial?

This trial is for adults with advanced solid tumors that have a specific RAS mutation. They should be in relatively good physical condition (ECOG status of 0 or 1), expected to live at least 12 weeks, and have measurable disease according to certain medical criteria. Their blood counts and organ functions must also meet the study's requirements.

Inclusion Criteria

My cancer can be measured for changes and I am fully active or restricted in physically strenuous activity only.
My doctor expects me to live for at least 12 more weeks.
My cancer has a confirmed RAS mutation.
See 2 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Dose Escalation

Participants receive multiple ascending doses of RO7673396 to determine the recommended dose for expansion

Until unacceptable toxicity or disease progression

Dose Expansion

Participants receive RO7673396 at the recommended dose to evaluate preliminary anti-tumor activity

Until unacceptable toxicity or disease progression

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • RO7673396
Trial Overview The trial is testing RO7673396, a new potential treatment for cancer. It has two parts: first, finding the best dose (Dose Escalation), then seeing how well it works at that dose on different types of tumors (Dose Expansion).
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Group I: Stage IIExperimental Treatment1 Intervention
Group II: Stage IExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Hoffmann-La Roche

Lead Sponsor

Trials
2,482
Recruited
1,107,000+
Headquarters
Basel, Switzerland
Known For
Precision medicine
Top Products
Avastin, Herceptin, Rituxan, Accu-Chek
Dr. Levi Garraway profile image

Dr. Levi Garraway

Hoffmann-La Roche

Chief Medical Officer since 2019

MD from the University of Basel

Dr. Thomas Schinecker profile image

Dr. Thomas Schinecker

Hoffmann-La Roche

Chief Executive Officer since 2023

PhD in Molecular Biology from New York University

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security